We have started screening for a new research study for those patients with fatty liver disease, also known as NAFLD and NASH. The study is a randomized, double-blind, controlled, multi-center phase 2 study evaluating the role of two medications called Roflumilast and pioglitazone.
Study candidates will receive one or both medicines, and will be evaluated to determine the degree of fat in the liver, as well as improvements in their liver enzymes (ALT and AST).
Participants will need to first meet all eligibility criteria of the study. Once enrolled in the study, all treatment related medicines, testing, and care will be paid for by the sponsor of the study. The study will last approximately 5 months.
If interest, contact our office at 713-794-0700 and ask for Paula.